Schrödinger, Inc. SDGR R2KR3KPHARMA
Company Overview
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Why Investors Should Care
Revenue has grown at a 20.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.33.
Recent Developments
- Dec 2025 Revenue of $255.87M (+23.3% YoY); net profit $-103.27M.
- Trailing 12 Months Year-on-year growth — revenue +7.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.03% |
| 1 Year: | 7.50% |
Stock Price Performance
| 1 Year: | +19.96% |
| 6 Months: | +101.87% |
| 3 Months: | +55.76% |
| 1 Month: | -19.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SDGR Schrödinger, Inc. R2KR3KPHARMA | 23.80 | -32.60 | $1.56B | 0.00% | -31.08% | -16.17% | 20.03% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.74M | 19.01M | 19.96M | 26.17M | 23.09M | 25.80M | 32.13M | 29.78M | 29.85M | 48.66M | 38.47M | 36.98M | 64.78M | 35.19M | 42.57M | 36.60M | 47.33M | 35.29M | - | 59.55M | 54.76M | 54.32M | 87.23M | 58.59M | 58.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.43M | 28.60M | 26.29M | 29.94M | 29.04M | - |
| Gross Profit | 13.00M | 9.85M | 10.71M | 15.62M | 13.58M | 15.27M | 16.16M | 11.98M | 11.12M | 27.98M | 17.13M | 17.20M | 45.69M | 13.81M | 23.64M | 18.89M | 31.34M | 17.73M | - | 31.12M | 26.16M | 28.04M | 57.29M | 29.55M | 32.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 82.01M | 79.06M | 73.99M | 74.45M | 78.34M | - |
| Operating Income | -5.61M | -13.96M | -11.29M | -11.80M | -17.09M | -15.45M | -23.91M | -30.34M | -34.67M | -28.64M | -43.47M | -46.16M | -30.50M | -61.13M | -56.19M | -67.43M | -52.73M | -68.42M | - | -50.89M | -52.90M | -45.95M | -17.16M | -48.79M | -41.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -49.30M | -51.37M | -44.48M | -15.72M | -47.32M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -59.78M | -42.89M | -32.63M | 32.97M | -59.62M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.00K | 287.00K | 162.00K | 462.00K | 408.00K | - |
| Net Income | -5.79M | -500.00K | -11.51M | -13.83M | -3.35M | 3.85M | -29.00K | -34.64M | -35.01M | -34.44M | -47.69M | -39.85M | 129.14M | 4.28M | -62.02M | -54.72M | -54.05M | -38.14M | - | -59.81M | -43.17M | -32.80M | 32.51M | -60.03M | 5.97M |
| Diluted EPS | - | - | -0.26 | - | - | 0.05 | - | -0.49 | -0.49 | -0.48 | -0.67 | -0.56 | 1.75 | 0.06 | -0.86 | -0.76 | -0.74 | -0.52 | - | -0.82 | -0.59 | -0.45 | - | -0.81 | 0.08 |
| R&D Expense | 8.44M | 9.53M | 10.35M | 13.70M | 16.66M | 17.02M | 21.45M | 21.09M | 23.22M | 27.82M | 31.12M | 32.88M | 40.74M | 42.70M | 46.83M | 50.61M | 50.84M | 50.98M | - | 45.84M | 43.14M | 42.76M | - | 43.82M | 41.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.54M | 108.09M | 137.93M | 180.96M | 216.67M | 207.54M | 255.87M |
| Gross Profit | 49.09M | 63.47M | 65.62M | 101.02M | 140.69M | 132.08M | 142.61M |
| Operating Income | -38.72M | -60.92M | -111.44M | -146.82M | -177.45M | -209.30M | -166.90M |
| Net Income | -24.57M | -24.46M | -100.39M | -149.19M | 40.72M | -187.12M | -103.27M |
| Diluted EPS | - | -0.41 | -1.42 | -2.10 | 0.54 | -2.57 | -1.41 |
| R&D Expense | 39.40M | 64.69M | 90.90M | 126.37M | 181.77M | 201.78M | 173.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 155.27M | 746.26M | - | 688.59M | 802.96M | 823.23M | 726.16M |
| Current Assets | - | - | - | - | 533.99M | 567.80M | 634.99M | 519.26M |
| Cash & Equivalents | - | 25.99M | 202.30M | - | 90.47M | 155.31M | 147.33M | 230.52M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 55.95M | 65.99M | 235.69M | 83.04M |
| Total Liabilities | - | 57.01M | 122.24M | - | 240.68M | 254.40M | 401.78M | 362.11M |
| Current Liabilities | - | 45.02M | 73.20M | - | 108.80M | 133.67M | 191.75M | 189.14M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 116.49M | 127.88M | 117.83M | 109.23M |
| Total Equity | -71.56M | -93.36M | 624.01M | - | 447.89M | 548.56M | 421.44M | 364.05M |
| Shares Outstanding | - | - | - | - | 71.33M | 72.14M | 72.87M | 73.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -26.06M | 16.76M | -70.67M | -119.68M | -136.73M | -157.37M | 13.90M |
| Investing Cash Flow | -53.85M | -381.72M | -16.81M | 90.02M | 193.03M | 148.84M | 57.90M |
| Financing Cash Flow | 28.68M | 541.27M | 7.95M | 2.11M | 9.05M | 10.12M | 2.93M |
| Capital Expenditure | -1.84M | -2.54M | -7.17M | -8.01M | -13.40M | -7.31M | -1.44M |
| Free Cash Flow | -27.89M | 14.22M | -77.84M | -127.70M | -150.14M | -164.68M | 12.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating Margin % | -45.3% | -56.4% | -80.8% | -81.1% | -81.9% | -100.8% | -65.2% |
| Net Margin % | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
| ROE % | 26.3% | -3.9% | - | -33.3% | 7.4% | -44.4% | -28.4% |
| ROCE % | -35.1% | -9.1% | - | -25.3% | -26.5% | -33.1% | -31.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.05% | 10.52M | $287.03M |
| 2 | Gates Foundation Trust | 10.65% | 6.98M | $190.46M |
| 3 | Rubric Capital Management LP | 9.76% | 6.40M | $174.59M |
| 4 | Vanguard Portfolio Management LLC | 5.78% | 3.79M | $103.32M |
| 5 | Sumitomo Mitsui Trust Group, Inc. | 4.13% | 2.71M | $73.82M |
| 6 | Amova Asset Management Americas Inc | 4.13% | 2.71M | $73.82M |
| 7 | Vanguard Capital Management LLC | 4.11% | 2.69M | $73.41M |
| 8 | State Street Corporation | 3.51% | 2.30M | $62.70M |
| 9 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.39% | 2.22M | $60.60M |
| 10 | ARK Investment Management, LLC | 3.29% | 2.15M | $58.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SDGR
Schrodinger, Inc. (SDGR) Stock Forecasts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNMnFkRjBnVHRhenlRNkg2SjNwMTVFNFVRWi1yS3U0UWZ6cnQ2WnVLRHVfNXNuVVk2bFdiUkxNVEY2VWtNazJuM1lTaGVKdUdPeEEyc2RSX1k3bXJjTTFqYlJuWjY4MmJRVUgzem1nRHB5ZXRSSzJ3NC14YzBVSWVROUl1RWtqQ2Z5b1hDd0…
Schrodinger Inc. Stock Grades | SDGR - Barron's
<a href="https://news.google.com/rss/articles/CBMitAJBVV95cUxQRzRTSWtKYWRTTmhNOEhZMTk3WU9ydEtURFFKWXhPOWNCRUc3Zl91b1ZTQnNDVjJYeXk2ampsYzBpQkN2b2pRZFZZcXhQLWhaRWZfdWJlR3BPd2xlRDNiVHJ2YkVIU05NUHNxMUp0b3NCQVJWem5zSFNBbTVMdHA1Q2pwTDNEeU9wUlY0eW…
Q3 results are scheduled for Nov. 4, with Schrödinger’s webcast at 4:30 p.m. ET. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNQ2FRc19VWVhBUTRJR3RxYThvdFVMNGl3b24zcWd4eGlTN2lpNmdDVTdfRzNCUEZfdFJpSmw5cTBOcU5jQnZUajkzSlRhNG44YlhzME9KWDRlYjJsaFVwVG9JTFZXcGgzV0Z5SUZXTF8zYmExdVdFd2RzbUEwaVg1T1dxUDUyWWwzR0t1Qm…
SDGR Stock: Schrödinger Hopes Its AI Agent Can Transform Drug Discovery - CMC Markets
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOcGVLNzEtb0dNdWlzT1d1N2NZNkpuclpsX2ZyX2xQVlRYVHIxUksya1RyVkJoVnZoc0QzWTJYOVJ0TTUtVDllM21NWlQ5VEdnUHdwU2xDdmhadVJYd29ZSkctSW9VUlJENHlsT3l0TWhsX184b0ZfdFV4dHRBQUJfNk5PQks0OUh2NWFBeE…
Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQUk9pcnJYR2pHR3dBTW8ta3k1V28zS3J4Mzk2SUhoUHNuN3lodzM1d2RnNjVuSXQtUjBSWFhCYTBzSWxZem1sc3A5QVg1ODNxeTBxQlZSUlo5T0VtaEEtM2ZXWTJnOUV2OFNCeTRmcXpaYy1icnhKd0hyZG1fWEpnVzBHZUg3eU9fTXpnaF…
SDGR Dec 2026 20.000 put (SDGR261218P00020000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBWcFN5Ul9kczFNb3VyZnVxVFdadml4eTZKZ0Y1WW9DTHl2a2NoeXpVWC12Z0duRWxobHUwM1FzV0NLSTJaNUpIQ0kwa3VHYWNEakh1TURtb2VQQk4zRnpvUE1vUnJKZw?oc=5" target="_blank">SDGR Dec 2026 20.000 put (SDG…
SDGR — Frequently Asked Questions
What is the current share price of Schrödinger, Inc. (SDGR)?
As of 2026-10-23 16:27 PDT, Schrödinger, Inc. (SDGR) trades at $23.80 on NasdaqGS. Its 52-week range is $11.07 to $32.60.
What is the market capitalisation of SDGR?
Schrödinger, Inc. (SDGR) has a market capitalisation of $1.56B on NasdaqGS.
What is the P/E ratio of SDGR?
SDGR trades at a trailing price-to-earnings (P/E) ratio of -32.60. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.43.
What is the return on equity (ROE) of SDGR?
SDGR has a return on equity (ROE) of -16.17%. Its return on capital employed (ROCE) is -31.08%.
Is SDGR a good stock to buy?
This page provides a data-driven analysis of Schrödinger, Inc. (SDGR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.